These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8235707)

  • 41. [The effectiveness of interferon-alpha therapy in Ph-positive chronic myeloid leukemia].
    Bogdanov KV; Frolova OI; Marinets OV; Ogorodnikova IuS; Afanas'ev BV; Zaritskiĭ AIu
    Vopr Onkol; 2003; 49(2):189-92. PubMed ID: 12785203
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current treatment of chronic myelogenous leukemia.
    Goldman JM
    Pathol Biol (Paris); 1989 Feb; 37(2):128-9. PubMed ID: 2469054
    [No Abstract]   [Full Text] [Related]  

  • 43. Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study Group.
    Hehlmann R; Willer A; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Hochhaus A; Tobler A; Lengfelder E; Berger U; Leib-Mösch C
    Leukemia; 1997 Apr; 11 Suppl 3():506-11. PubMed ID: 9209440
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interferon alpha in the treatment of chronic myelogenous leukemia.
    Robak T
    Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapy-related changes of CD20+ and CD45RO+ lymphocyte subsets in chronic myeloid leukemia (CML): an immunohistochemical and morphometric study on sequential trephine biopsies of the bone marrow.
    Thiele J; Kvasnicka HM; Schmitt-Graeff A; Cvetanovska G; Blum N; Schaefer HE
    Mod Pathol; 2000 Aug; 13(8):888-96. PubMed ID: 10955456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.
    Farag SS; Ruppert AS; Mrózek K; Carroll AJ; Pettenati MJ; Le Beau MM; Peterson BL; Powell BL; Ozer H; Silver RT; Larson RA; Bloomfield CD;
    Int J Oncol; 2004 Jul; 25(1):143-51. PubMed ID: 15201999
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.
    Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Heinze B; Georgii A
    Blood; 1993 Jul; 82(2):398-407. PubMed ID: 8329700
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia.
    Rodriguez J; Cortes J; Talpaz M; O'Brien S; Smith TL; Rios MB; Kantarjian H
    Clin Cancer Res; 2000 Jan; 6(1):147-52. PubMed ID: 10656443
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Progress with interferon in CML--results of the MRC UK CML III study.
    Shepherd PC; Richards SM; Allan NC
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S15-8. PubMed ID: 8769693
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
    Schulze E; Krahl R; Thalmeier K; Helbig W
    Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group.
    Hehlmann R; Heimpel H; Hossfeld DK; Hasford J; Kolb HJ; Löffler H; Pralle H; Queisser W; Hochhaus A; Tichelli A; Fett W; Schmitz N; Reiter A; Griesshammer M; Pfeifer W; Bümler M; Kamp T; Tobler A; Eimermacher H; Kuse R; Berger U; Ansari H
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S21-4. PubMed ID: 8769695
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group.
    Hehlmann R; Ansari H; Hasford J; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Reiter A; Hochhaus A
    Br J Haematol; 1997 Apr; 97(1):76-85. PubMed ID: 9136944
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
    Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
    Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Pure red cell aplasia occurring during the course of chronic myelogenous leukemia].
    Yasuyama M; Kawauchi K; Takei K; Ogasawara T; Ohkawa S
    Rinsho Ketsueki; 2004 Jan; 45(1):66-71. PubMed ID: 14999937
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis and validation of prognostic factors for CML. German CML Study Group.
    Hasford J; Ansari H; Pfirrmann M; Hehlmann R
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S49-54. PubMed ID: 8769702
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of chronic myeloid leukaemia.
    Goldman JM
    Blood Rev; 1994 Mar; 8(1):21-9. PubMed ID: 8205007
    [No Abstract]   [Full Text] [Related]  

  • 58. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
    Onida F; Ball G; Kantarjian HM; Smith TL; Glassman A; Albitar M; Scappini B; Rios MB; Keating MJ; Beran M
    Cancer; 2002 Oct; 95(8):1673-84. PubMed ID: 12365015
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intensive treatment in order to minimize the Ph-positive clone in CML. Danish-Swedish CML Group.
    Simonsson B; Oberg G; Björeman M; Björkholm M; Carneskog J; Gahrton G; Hast R; Karl H; Lanng-Nielsen J; Löfvenberg E; Malm C; Turesson I; Udén AM; Vilén L; Weis-Bjerrum O
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S63-4. PubMed ID: 8769705
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.